A team of University of Minnesota Medical School researchers led by Dr. David R. Boulware successfully tested a new antifungal therapy to treat fungal meningitis.
The research team tested a new oral formulation of the antifungal medication amphotericin among people who had HIV and cryptococcal meningitis—a common fungal infection around the brain. Cryptococcal meningitis is the most common cause of central nervous system infection in people living with HIV worldwide. In this randomized trial, 141 HIV-positive people with cryptococcal meningitis received the oral amphotericin combined with oral flucytosine
While at Wabash, Boulware was a member of Phi Kappa Psi and majored in chemistry. He is now an infectious disease expert and distinguished associate professor at the University of Minnesota.
